Left-right asymmetric ventricular expression of CARP in the piglet heart: regional response to experimental heart failure.
OBJECTIVE
Cardiac ankyrin repeat protein (CARP), whose expression is down-regulated in response to doxorubicin (Dox) in vitro, has been proposed to be a marker of experimentally-induced cardiac hypertrophy in rodent models. In piglets, the rapid hypertrophy rate of the left ventricle (LV) as compared to that of the right ventricle (RV) represents a natural model of asymmetric ventricular enlargement. We tested whether CARP expression correlates with postnatal ventricular hypertrophy and to what extent CARP can be sensitive to Dox treatment in vivo.


METHODS
CARP mRNA and protein levels were quantified (by Northern blot hybridization, semi-quantitative RT-PCR and Western blot) in the piglet heart, both during early postnatal development and upon Dox-induced cardiomyopathy (Dox-CM).


RESULTS
The study revealed: (1) significantly augmented CARP mRNA and protein levels in the LV compared to the RV resulting in left vs. right asymmetry in ventricular CARP expression throughout early postnatal development; (2) dose- and chamber-dependent CARP mRNA and protein enrichment in ventricular myocardium in response to Dox; and (3) abolishment of asymmetric patterns of ventricular CARP expression at heart failure resulting from Dox-CM.


CONCLUSIONS
(1) CARP is differentially regulated in the LV and RV during both postnatal development and disease; and (2) monitoring of ventricular CARP expression patterns can be used for further analysis of transition from compensated to overt heart failure.
Developmental Biology Unit, Institute of Health Sciences, University of La Coruña, Campus de Oza, Building 'El Fortín', Las Xubias s/n, La Coruña 15006, Spain.
Mario
M
Torrado
Eduardo
E
López
Alberto
A
Centeno
Alfonso
A
Castro-Beiras
Alexander T
AT
Mikhailov
D000818:Animals; D000831:Animals, Newborn; D000903:Antibiotics, Antineoplastic / Q000009:adverse effects* / Q000494:pharmacology / Q000627:therapeutic use; D015152:Blotting, Northern; D015153:Blotting, Western; D006332:Cardiomegaly / Q000188:drug therapy*; D003001:Cloning, Molecular; D004317:Doxorubicin / Q000009:adverse effects* / Q000494:pharmacology / Q000627:therapeutic use; D018507:Gene Expression Regulation, Developmental; D006333:Heart Failure / Q000378:metabolism* / Q000503:physiopathology; D023421:Models, Animal; D009206:Myocardium / Q000378:metabolism*; D009687:Nuclear Proteins / Q000187:drug effects / Q000235:genetics / Q000378:metabolism*; D012333:RNA, Messenger / Q000378:metabolism; D011897:Random Allocation; D012097:Repressor Proteins / Q000187:drug effects / Q000235:genetics / Q000378:metabolism*; D020133:Reverse Transcriptase Polymerase Chain Reaction; D013552:Swine
D000903:Antibiotics, Antineoplastic; D009687:Nuclear Proteins; D012333:RNA, Messenger; D012097:Repressor Proteins; D004317:Doxorubicin